GlyNAC-et (Glycine + NACET) 500mg + 100mg - 100 capsules

Glutathione synthesis by dual supply of limiting precursors

The primary mechanism of GlyNAC-et operates through the coordinated supply of the two amino acids that typically limit glutathione synthesis in human tissues: glycine and cysteine. Glutathione biosynthesis occurs in two sequential enzymatic steps catalyzed by glutamate-cysteine ​​ligase (GCL) and glutathione synthetase (GS). In the first step, considered the rate-limiting step, GCL catalyzes the formation of a peptide bond between the γ-carboxyl group of glutamate and the amino group of cysteine, generating γ-glutamylcysteine ​​with the consumption of ATP. This enzyme is composed of a catalytic subunit (GCLC) and a modulatory subunit (GCLM), and its activity is subject to feedback inhibition by glutathione itself, constituting a refined homeostatic mechanism. In the second step, glutathione synthetase links glycine to the dipeptide γ-glutamylcysteine ​​via a conventional peptide bond, completing the structure of the glutathione tripeptide (γ-L-glutamyl-L-cysteinylglycine). Cysteine ​​availability is often the most significant bottleneck in this process, particularly because this amino acid is easily oxidized and must be maintained in its reduced form to participate effectively in synthesis. NACET addresses this limitation by providing N-acetylcysteine, which, once deacetylated intracellularly by esterases, releases cysteine ​​in a protected environment. Simultaneously, the provided glycine eliminates a second potential limitation, since although this amino acid can be synthesized endogenously from serine, multiple metabolic demands compete for the available glycine pool, including the synthesis of collagen, purines, heme, and detoxification conjugates. By supplying both precursors in a coordinated manner, GlyNAC-et removes the restrictions at both steps of the biosynthetic pathway, allowing glutathione production to proceed at a rate limited only by intrinsic enzyme activity and the availability of glutamate, which is rarely scarce.

Improved permeability of lipid membranes and crossing of the blood-brain barrier

Chemical modification of N-acetylcysteine ​​by esterification with an ethyl group yields NACET, whose pharmacokinetic properties differ substantially from its unmodified precursor. N-acetylcysteine, being a relatively hydrophilic molecule with ionizable groups, exhibits limited membrane permeability and depends significantly on specific amino acid transporters for its cellular uptake. This can represent a limiting factor in tissues with reduced expression of these transporters or in specific cellular compartments such as mitochondria. The addition of the ethyl ester group considerably increases the octanol-water partition coefficient of the molecule, increasing its lipophilicity and allowing the passage of lipid membranes by passive diffusion. This characteristic is particularly relevant for crossing the blood-brain barrier, a highly selective structure formed by endothelial cells with tight junctions that restrict the passage of hydrophilic molecules. Once NACET crosses cell membranes and reaches the cytoplasm, ubiquitous esterase enzymes catalyze the hydrolysis of the ester bond, releasing N-acetylcysteine ​​and ethanol in amounts that do not generate pharmacologically relevant concentrations. This "lipophilic prodrug" strategy allows it to circumvent transport limitations and reach cellular and tissue compartments that would be less accessible to conventional N-acetylcysteine, specifically including mitochondria, where glutathione concentration is critical for protection against oxidative stress generated by the electron transport chain. The net result is improved biodistribution with preferential accumulation in tissues with high metabolic demand and high production of reactive oxygen species.

Direct neutralization of reactive oxygen and nitrogen species

Glutathione synthesized from precursors provided by GlyNAC-et acts as the most abundant non-enzymatic antioxidant in biological systems, operating through multiple mechanisms of reactive species neutralization. The thiol group (-SH) of cysteine ​​in glutathione represents the chemically reactive site that confers its reducing properties. This thiol group can donate a hydrogen atom to free radicals such as the hydroxyl radical (•OH), the superoxide anion (O₂•⁻), and lipid peroxyl radicals (ROO•), converting them into stable species as glutathione is oxidized to its disulfide form (GSSG, oxidized glutathione). This reaction is particularly important in the context of lipid peroxidation, where peroxyl radicals can propagate chain reactions that compromise the integrity of cell membranes. Glutathione interrupts these cascades by reducing peroxyl radicals to relatively stable lipid hydroperoxides, which are subsequently processed by glutathione peroxidase enzymes. Beyond the direct reduction of radicals, glutathione reacts with reactive nitrogen species such as nitrogen dioxide (NO₂) and peroxynitrite (ONOO⁻), the latter formed by the reaction of nitric oxide with the superoxide anion and capable of nitrating tyrosine residues in proteins, thus altering their function. Glutathione's ability to interact with peroxynitrite protects against the nitration of critical proteins and preserves the bioavailability of nitric oxide for vascular signaling functions. Crucially, the glutathione system operates catalytically due to the presence of the enzyme glutathione reductase, which uses NADPH as a cofactor to regenerate reduced glutathione from GSSG, allowing a single glutathione molecule to participate in multiple reduction-oxidation-reduction cycles and greatly amplifying its protective efficacy.

Enzymatic cofactor for glutathione peroxidases and glutathione S-transferases

Glutathione not only acts as a direct antioxidant but also functions as an essential substrate for two enzyme families fundamental to cellular defense. Glutathione peroxidases (GPx) are a family of selenium-dependent enzymes that catalyze the reduction of hydrogen peroxide (H₂O₂) and lipid peroxides (ROOH) to water and their corresponding alcohols, using glutathione as the reducing agent. Multiple GPx isoforms exist with distinct subcellular locations: GPx1 is cytosolic and mitochondrial, GPx2 is gastrointestinal, GPx3 is extracellular plasma, and GPx4 is particularly important due to its unique ability to directly reduce complex lipid hydroperoxides in membranes, including phospholipid and cholesterol hydroperoxides. The GPx-catalyzed reaction is highly efficient and prevents the accumulation of peroxides that could otherwise decompose via Fenton reactions to generate extremely reactive hydroxyl radicals. The second crucial enzyme family is the glutathione S-transferases (GSTs), which catalyze the conjugation of glutathione with a wide variety of electrophilic compounds, including byproducts of oxidative metabolism such as 4-hydroxynonenal (a lipid peroxidation product), as well as xenobiotics and phase I metabolites. This conjugation reaction increases the water solubility of the compounds and marks them for cellular export via ABC transporters, constituting a critical phase II detoxification mechanism. GSTs also possess selenium-independent peroxidase activity that complements the function of GPxs. The availability of glutathione at adequate concentrations is absolutely critical for the function of both enzyme families, since when glutathione is depleted, these enzymes cannot perform their catalytic function regardless of their own expression or intrinsic activity, making glutathione a master regulator of these enzyme protection pathways.

Regeneration of oxidized antioxidants and maintenance of the redox network

Glutathione occupies a central position in the architecture of the cellular antioxidant network through its ability to regenerate other antioxidants after they are oxidized by neutralizing free radicals. α-Tocopherol (vitamin E), located predominantly in lipid membranes, donates its phenolic hydrogen to lipid peroxyl radicals, becoming the tocopheroxyl radical. This radical can be reduced back to α-tocopherol by ascorbate (vitamin C), which in turn is oxidized to the ascorbyl or dehydroascorbate radical. Glutathione closes the cycle by reducing dehydroascorbate back to ascorbate, either directly or through the action of dehydroascorbate reductase. This cascade of electron transfers amplifies the overall antioxidant capacity of the system, allowing fat-soluble and water-soluble vitamins to work synergistically with glutathione acting as the ultimate reducing reservoir. Beyond its role in vitamins, glutathione participates in the recycling of oxidized lipoic acid and maintains enzymes with critical thiol groups in their functional reduced state. Glutaredoxin, an oxidoreductase that uses glutathione as a cofactor, specifically catalyzes the reduction of S-glutathionylated proteins, a type of redox-dependent post-translational modification that regulates the activity of numerous proteins. This integrated antioxidant regeneration system means that glutathione levels determine not only direct antioxidant capacity but also the functional effectiveness of the entire antioxidant defense system, justifying its designation as the cellular "master antioxidant." Glutathione depletion simultaneously compromises multiple layers of antioxidant protection, while its restoration by GlyNAC-et can potentially reconstitute the functionality of the entire network.

Modulation of redox signaling by protein S-glutathionylation

S-glutathionylation represents a reversible post-translational modification where glutathione forms a mixed disulfide bond with specific cysteine ​​residues in target proteins, altering their conformation, activity, or interactions. This mechanism has emerged as an important redox signaling system that allows cells to respond dynamically to changes in oxidative status. The S-glutathionylation reaction can occur spontaneously when protein cysteines are oxidized to sulfenic acid (Cys-SOH) in the presence of moderate oxidative stress, followed by nucleophilic attack by glutathione, or it can be enzymatically catalyzed by specific glutathione S-transferases. This modification has been documented in hundreds of proteins, including metabolic enzymes, transcription factors, structural proteins, and ion channels. For example, S-glutathionylation of the p65 subunit of the transcription factor NF-κB inhibits its binding to DNA and modulates the expression of inflammatory genes, while S-glutathionylation of actin influences cytoskeleton dynamics. In the metabolic context, S-glutathionylation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) during oxidative stress inactivates this glycolytic enzyme, diverting carbon flow to the pentose phosphate pathway where NADPH, necessary for glutathione regeneration, is generated, constituting an elegant feedback mechanism. Deglutathionylation, catalyzed primarily by glutaredoxins, reverses this modification and restores the original protein function. The reduced glutathione/oxidized glutathione (GSH/GSSG) ratio determines cellular redox potential and directly influences the balance between glutathionylation and deglutathionylation, making the glutathione system a molecular rheostat that modulates the activity of numerous signaling pathways in response to the cell's metabolic and oxidative state. By raising reduced glutathione levels, GlyNAC-et could influence the S-glutathionylation status of multiple redox-sensitive proteins, with functional consequences ranging from metabolism to gene transcription.

Maintenance of mitochondrial membrane potential and protection against permeabilization

Mitochondria are especially vulnerable to oxidative stress due to their role as the primary source of reactive oxygen species in most cells, generated as byproducts of the electron transport chain. Mitochondrial glutathione, which represents approximately 10 to 15 percent of total cellular glutathione but is critical for mitochondrial function, exists in a separate pool from the cytosolic pool and must be actively imported from the cytoplasm by specific transporters, including the dicarboxylate and 2-oxoglutarate transporters. Mitochondrial glutathione concentration declines more rapidly than cytosolic glutathione during aging and oxidative stress, compromising the ability of these organelles to neutralize reactive species generated during oxidative phosphorylation. Depletion of mitochondrial glutathione sensitizes the mitochondrial permeability transition pore (mPTP), a megachannel whose prolonged opening causes depolarization of the inner mitochondrial membrane, osmotic swelling, rupture of the outer membrane, and release of pro-apoptotic factors such as cytochrome c. Glutathione protects against mPTP opening through multiple mechanisms: it neutralizes reactive species that could oxidize regulatory components of the pore, maintains critical thiol groups in pore structural proteins in a reduced state, and indirectly modulates mitochondrial calcium homeostasis. Mitochondrial glutathione peroxidases, particularly GPx4, protect inner mitochondrial membrane lipids from peroxidation, preserving their structural integrity and the barrier properties necessary to maintain the proton gradient that drives ATP synthesis. By providing the precursors to specifically raise the mitochondrial glutathione pool, GlyNAC-et could support mitochondrial stability, oxidative phosphorylation efficiency, and cellular resistance to pro-apoptotic stimuli—mechanisms that connect antioxidant status with cellular bioenergetics and viability.

Neuromodulation through activation of inhibitory glycine receptors and facilitation of NMDA receptors

Glycine functions as a neurotransmitter with dual actions in the central nervous system, operating both as an inhibitory ligand at glycinergic receptors and as a necessary co-agonist at NMDA glutamatergic receptors. Inhibitory glycine receptors are chloride-permeable ion channels that, when activated by glycine binding, allow the influx of chloride ions into the neuron, hyperpolarizing the membrane and reducing the likelihood of the neuron generating action potentials. These receptors are abundantly expressed in the spinal cord, brainstem, and some forebrain regions, where they mediate rapid inhibitory neurotransmission, particularly in sensory processing and motor control circuits. Glycine released at inhibitory synapses is rapidly reuptaken by the glycine transporters GlyT1 and GlyT2, which terminate signaling and maintain low extrasynaptic concentrations. In contrast, NMDA receptors are cation channels that require the simultaneous binding of glutamate (to the glutamate site) and a co-agonist to the glycine site (which can be occupied by either glycine or D-serine) to be fully activated. They also require membrane depolarization to remove the magnesium block from the channel pore. Once open, NMDA receptors allow the influx of sodium and calcium, with the latter initiating signaling cascades that mediate synaptic plasticity, including long-term potentiation and long-term depression—cellular processes fundamental to learning and memory. The availability of glycine or D-serine in the extracellular space can modulate NMDA receptor activity, with the GlyT1 transporter regulating perisynaptic glycine concentrations and thus influencing the activation tone of these receptors. By increasing systemic glycine availability, GlyNAC-et could influence both systems: by enhancing inhibitory glycinergic neurotransmission in regions where glycine receptors predominate, and by modulating co-agonist site occupation at NMDA receptors, with potential consequences for sensory information processing, motor control, vigilance states, and NMDA-dependent plasticity processes that underlie higher cognitive functions.

Immunomodulation via glycine receptors in innate immune cells

The discovery of functional glycine receptors in cells of the innate immune system, particularly macrophages, neutrophils, and hepatic Kupffer cells, has revealed an unexpected mechanism by which this amino acid can modulate inflammatory responses. These receptors in immune cells are structurally similar to inhibitory neuronal glycine receptors, being ligand-gated pentameric chloride channels. When glycine binds to these receptors in macrophages or neutrophils, it induces chloride-mediated membrane hyperpolarization, which has significant consequences for cell signaling. This hyperpolarization can antagonize the cytosolic calcium elevation induced by pro-inflammatory stimuli such as lipopolysaccharide (LPS), as the electrochemical driving force for calcium influx is reduced. Since many innate immune cell responses, including the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and the generation of reactive oxygen species by NADPH oxidase, critically depend on calcium signals, modulation of these signals by glycine can attenuate the magnitude of the inflammatory response. Experimental studies have shown that glycine administration can reduce the production of pro-inflammatory cytokines by activated macrophages and the accumulation of neutrophils at sites of inflammation. Furthermore, glycine appears to influence the activation of the transcription factor NF-κB in immune cells, a master regulator of inflammatory gene expression. This immunomodulatory mechanism of glycine is conceptually distinct from pharmacological immunosuppression, representing instead a physiological modulation that could attenuate excessive or prolonged inflammatory responses while preserving fundamental immune responsiveness. By providing glycine in sufficient quantities to activate these receptors in immune cells, GlyNAC-et could influence the balance between pro-inflammatory and anti-inflammatory responses, with implications for contexts where excessive inflammation contributes to pathophysiology.

Collagen synthesis and maintenance of extracellular matrix integrity

Glycine represents approximately 33 percent of the amino acid residues in collagen, the most abundant structural protein in mammals and a major component of the extracellular matrix in connective tissues. The unique structure of collagen consists of a triple helix where three polypeptide chains (α chains) coil around each other. This conformation is made possible by the repetition of the Gly-XY motif, where X is frequently proline and Y is frequently hydroxyproline. The presence of glycine at every third position is mandatory because only this amino acid, lacking a side chain beyond a single hydrogen atom, is small enough to fit within the densely packed interior of the triple helix. Collagen biosynthesis is a complex process that begins with the transcription of collagen genes (more than 28 distinct types in humans) and the translation of pro-α chains in the endoplasmic reticulum. During synthesis, specific proline and lysine residues are hydroxylated by prolyl hydroxylases and lysyl hydroxylases in reactions that require vitamin C, α-ketoglutarate, and iron as cofactors, generating hydroxyproline and hydroxylysine, which are critical for the thermal stability and cross-linking of mature collagen. The pro-α chains assemble into trimers that form the triple helix, and these procollagens are secreted into the extracellular space where specific peptidases cleave the terminal propeptides, allowing the collagen molecules to self-assemble into fibrils that are subsequently stabilized by covalent cross-linking catalyzed by lysyl oxidase. The demand for glycine for collagen synthesis is extraordinarily high, with an estimated 10 to 15 grams required daily to produce the amount of collagen necessary to maintain normal connective tissue renewal in an adult. This demand substantially exceeds the endogenous capacity to synthesize glycine from serine, suggesting that glycine availability may limit collagen synthesis, particularly during periods of accelerated tissue repair, such as after injury or intense exercise. By providing exogenous glycine, GlyNAC-et could support de novo collagen synthesis and the maintenance of collagen-rich tissues, including skin, tendons, ligaments, cartilage, blood vessels, and bone, where collagen provides tensile strength and organized structure essential for mechanical function.

Phase II conjugation in hepatic and renal detoxification

Glycine participates as a conjugating agent in multiple phase II detoxification reactions catalyzed by enzymes of the acyltransferase family. Glycine N-acyltransferase, abundantly expressed in the liver and kidneys, catalyzes the conjugation of glycine with various carboxylic acids, including bile acids (forming taurocholate and glycoconjugates), benzoate (forming hippurate or hippuric acid), salicylate, and other organic acids derived from both endogenous metabolism and xenobiotics. These conjugation reactions transform relatively hydrophobic compounds into more water-soluble conjugates that can be efficiently excreted by the kidneys in urine or by the liver in bile, constituting a critical mechanism for the elimination of metabolic end products and potentially toxic exogenous compounds. The conjugation process first requires the activation of the carboxylic acid by forming an acyl-CoA ester using ATP and coenzyme A, followed by the transfer of the acyl group to glycine, releasing free CoA. The synthesis of glycine-conjugated bile acids represents a particularly important pathway: the primary bile acids (cholic and chenodeoxycholic) synthesized from cholesterol in the liver are predominantly conjugated with glycine or taurine before their secretion in bile. This conjugation dramatically increases their water solubility, reduces their inherent toxicity, prevents their precipitation in the biliary tract, and enhances their ability to emulsify dietary lipids in the small intestine. The excretion of conjugated bile acids in feces represents one of the few mechanisms by which excess cholesterol can be eliminated from the body. The capacity for conjugation depends directly on glycine availability, and it has been estimated that approximately 500 to 600 milligrams of glycine are consumed daily in adults alone for the synthesis of conjugated bile acids. During conditions of high detoxification load, such as exposure to drugs that require conjugation or the accumulation of oxidative metabolism products, the demand for glycine for conjugation can increase substantially, potentially competing with other metabolic functions of this amino acid. By supplementing with glycine, GlyNAC-et could support the phase II detoxification capacity of the liver and kidneys, ensuring that conjugation pathways are not limited by substrate availability and maintaining the efficiency of the elimination of endogenous and exogenous compounds.

Purine biosynthesis and one-carbon metabolism

Glycine is integrally involved in the de novo synthesis of purine nucleotides (adenine and guanine), the building blocks of DNA, RNA, and energy-carrying nucleotides such as ATP and GTP. In the purine biosynthetic pathway, glycine is fully incorporated into the emerging purine ring structure, contributing the carbon atoms at positions C4 and C5 and the nitrogen atom at position N7 of the purine base. The first committed step of purine synthesis involves the condensation of 5-phosphoribosyl-1-pyrophosphate (PRPP) with glutamine to form 5-phosphoribosylamine, followed by a series of ten enzymatic reactions that gradually build the characteristic bicyclic purine ring. In the third step of this sequence, glycine is condensed with phosphoribosylamine by the enzyme glycinamide ribonucleotide synthetase (GARS) in an ATP-consuming reaction, forming glycinamide ribonucleotide (GAR). This is the only reaction in the pathway where an entire amino acid is directly incorporated into the product structure, highlighting glycine's unique structural role in purine biosynthesis. Subsequently, additional carbon and nitrogen atoms derived from other sources (formyltetrahydrofolate, glutamine, CO₂, aspartate) are progressively added until inosine monophosphate (IMP), the common precursor of adenosine and guanosine monophosphates, is complete. The demand for purines is particularly high in rapidly dividing cells (where DNA replication requires large amounts of nucleotides), in activated immune cells, and in tissues with high cell turnover, such as the gastrointestinal tract. Beyond its direct incorporation into purines, glycine also participates in one-carbon metabolism through its reversible interconversion with serine, catalyzed by serine hydroxymethyltransferase (SHMT), which exists in cytosolic and mitochondrial isoforms. This reaction transfers a methylene group from serine to tetrahydrofolate (THF), generating glycine and 5,10-methylene-THF. The latter is an essential one-carbon donor for thymidylate synthesis (required for DNA) and for mitochondrial NADPH production via the glycine cleavage pathway. Mitochondrial glycine metabolism by the glycine cleavage system (GCS) generates CO₂, ammonia, and a methylene group transferred to THF, providing one-carbon units for biosynthesis. By supplying exogenous glycine, GlyNAC-et could support both purine synthesis and the flexibility of one-carbon metabolism—fundamental metabolic functions for cell proliferation, DNA repair, protein synthesis, and multiple biosynthetic pathways that depend on one-carbon donors.

Heme synthesis and regulation of oxygen transport

Glycine is an essential substrate for the biosynthesis of heme, the iron-containing structure that allows hemoglobin to bind oxygen reversibly, myoglobin to store oxygen in muscles, and numerous enzymes (cytochromes, peroxidases, catalases, nitric oxide synthases) to carry out critical redox reactions. Heme synthesis begins in the mitochondria with the condensation of glycine and succinyl-CoA (an intermediate of the Krebs cycle) catalyzed by the enzyme δ-aminolevulinate synthase (ALAS) to form δ-aminolevulinate (ALA) with the release of CO₂ and CoA. This reaction requires pyridoxal phosphate (vitamin B6) as a cofactor and represents the rate-limiting and regulated step of the entire heme synthesis pathway. Two ALA molecules are subsequently condensed by ALA dehydratase to form porphobilinogen, and four molecules of this are assembled into a porphyrin ring through a series of reactions that occur alternately in the cytoplasm and mitochondria. Finally, the resulting protoporphyrin IX is metallized with ferrous iron (Fe²⁺) by mitochondrial ferrochelatase to complete the heme group. Adult human hemoglobin is a tetramer composed of two α subunits and two β subunits, each containing a heme group capable of binding one oxygen molecule, allowing each hemoglobin molecule to transport four O₂ molecules. Erythrocytes have a lifespan of approximately 120 days, requiring the continuous production of new red blood cells in the bone marrow (erythropoiesis), a process that demands massive hemoglobin synthesis. It is estimated that approximately five percent of all body glycine is used for heme synthesis, and glycine availability can influence the efficiency of this process. Beyond hemoglobin, hepatic cytochrome P450 enzymes that metabolize drugs and xenobiotics, mitochondrial electron transport chain cytochromes that generate ATP, and other hemoproteins such as catalase that breaks down hydrogen peroxide, all depend on continuous heme synthesis. By providing glycine, GlyNAC-et could support heme biosynthesis and, by extension, oxygen-carrying capacity, the function of heme-dependent enzymes, and mitochondrial bioenergetics that rely on functional cytochromes.

Modulation of nitric oxide homeostasis through S-nitrosoglutathione formation

Glutathione plays a crucial role in the storage, stabilization, and transport of nitric oxide (NO), a gaseous signaling molecule with multiple physiological functions, including vasodilation, inhibition of platelet aggregation, neurotransmission, and regulation of immune responses. NO is synthesized by nitric oxide synthases (NOS) from L-arginine and oxygen, but due to its highly reactive free radical nature, it has an extremely short half-life in biological systems (seconds) and reacts rapidly with molecular oxygen, superoxide, hemoglobin, and protein thiol groups. An important pathway for NO stabilization is its reaction with the thiol group of glutathione to form S-nitrosoglutathione (GSNO), a thiol-bound form of NO that is more stable and can act as a mobile reservoir and donor of NO bioactivity. Gns-nitrosylated glutathione (GSNO) can form through several mechanisms: direct reaction of nitric oxide (NO) with glutathione in the presence of oxygen and transition metals, or transnitrosylation from S-nitrosylated proteins. Once formed, GSNO can circulate in the plasma and penetrate cell membranes, effectively transporting NO to sites distant from its synthesis. GSNO can release NO in a controlled manner or transfer the nitrous group to cysteine ​​residues in target proteins through transnitrosylation reactions, a process called protein S-nitrosylation that modifies the function of numerous proteins, including metabolic enzymes, ion channels, transcription factors, and structural proteins. S-nitrosylation represents a redox signaling mechanism analogous to phosphorylation, with broad functional consequences. The enzyme GSNO reductase (GSNOR) degrades GSNO to oxidized glutathione and ammonia, thereby regulating glutathione levels and indirectly modulating protein S-nitrosylation and NO bioavailability. By raising glutathione levels, GlyNAC-et could influence the cardiovascular system's ability to form and maintain GSNO, potentially affecting the effective bioavailability of NO and its multiple effects on vascular tone, endothelial function, leukocyte adhesion, and platelet aggregation, thus connecting antioxidant status with vascular and cardiovascular physiology.

Glutathione regeneration and synergistic antioxidant protection

• Vitamin C Complex with Camu Camu: Vitamin C plays a crucial role in maintaining and regenerating glutathione levels through multiple synergistic mechanisms with GlyNAC-et. Studies have documented that supplementation with 500 mg of ascorbic acid can raise glutathione levels in erythrocytes by approximately 50%, establishing a stoichiometric relationship where each change of one ascorbate molecule is accompanied by a change of approximately 0.5 glutathione molecules. This effect is due to the fact that vitamin C not only acts as a direct antioxidant but also protects and regenerates oxidized glutathione back to its active reduced form, thus amplifying the effectiveness of the precursors provided by GlyNAC-et. In addition, vitamin C can directly reduce oxidized glutathione (GSSG) and regenerate other antioxidants such as vitamin E, creating an integrated antioxidant network where glutathione synthesized from glycine and NACET operates with maximum efficiency thanks to the reducing environment maintained by ascorbate.

• Essential Minerals (especially Selenium): Selenium is an absolutely essential cofactor for the glutathione peroxidase (GPx) enzyme family, which uses glutathione as a substrate to catalyze the reduction of hydrogen peroxide and lipid peroxides. Without adequate selenium, these selenium-dependent enzymes cannot function efficiently, regardless of how high glutathione levels are, making selenium a critical determinant of the functional capacity of the glutathione system. The combination of GlyNAC-et with selenium creates a bidirectional synergy: the glutathione precursors ensure abundant substrate for GPx, while selenium ensures that these enzymes can effectively use that glutathione to neutralize reactive oxygen species. This relationship is particularly important in tissues with high peroxide production, such as the liver, kidneys, and lungs, where GPx represent a primary antioxidant line of defense against continuous oxidative stress.

• CoQ10 + PQQ: Coenzyme Q10 and the pyrroloquinoline quinone operate synergistically with the glutathione system in mitochondrial protection, creating complementary layers of antioxidant defense in these critical organelles. CoQ10 functions as a lipophilic antioxidant in the inner mitochondrial membranes and as an electron carrier in the respiratory chain, while PQQ stimulates mitochondrial biogenesis and acts as a redox cofactor. Glutathione synthesized from GlyNAC-et provides protection in the mitochondrial matrix and intermembrane space, compartments where CoQ10 is less abundant. This complementary spatial distribution ensures that all mitochondrial regions are protected: CoQ10 + PQQ protect the lipid membranes and the electron transport chain machinery, while glutathione defends soluble proteins and mitochondrial DNA. Furthermore, the reduction of mitochondrial oxidative stress through this combination promotes a more efficient production of ATP, which in turn provides the energy needed for the continuous synthesis of glutathione, closing a virtuous cycle of bioenergetic optimization and antioxidant defense.

• Alpha-lipoic acid: Alpha-lipoic acid exhibits exceptional multidimensional synergy with GlyNAC-et due to its unique ability to regenerate oxidized glutathione, enhance glutathione synthesis, and function as a direct antioxidant in both aqueous and lipid compartments. The lipoic acid/dihydrolipoic acid redox pair can directly recycle oxidized glutathione (GSSG) back to reduced glutathione (GSH), extending the lifespan and efficacy of glutathione synthesized from the precursors in GlyNAC-et. Furthermore, research has shown that alpha-lipoic acid can increase the expression of enzymes involved in glutathione synthesis, thereby enhancing the effect of providing glycine and N-acetylcysteine. This molecule also regenerates oxidized vitamins C and E, creating an "antioxidant defense network" where multiple antioxidants mutually regenerate each other, with glutathione playing a central role. The combination of GlyNAC-et with alpha-lipoic acid is particularly valuable in contexts of high oxidative stress where the antioxidant recycling capacity may be as important as the de novo synthesis of new antioxidants.

One-carbon metabolism and transsulfuration pathway

• B-Active: Activated B Vitamin Complex: Vitamins B6, B9 (folate), and B12 are absolutely essential cofactors for the transsulfuration pathway that converts homocysteine ​​to cysteine, the limiting amino acid for glutathione synthesis. Vitamin B6 (as pyridoxal-5-phosphate) is a required cofactor for the enzymes cystathionine β-synthase and cystathionine γ-lyase, which catalyze the two sequential steps of transsulfuration. Methylfolate and vitamin B12 are required for the remethylation of homocysteine ​​to methionine, thus regulating the flow of homocysteine ​​into the transsulfuration pathway versus remethylation. This complex interconnection means that deficiencies in these B vitamins can create bottlenecks that limit the endogenous synthesis of cysteine ​​and, by extension, glutathione, even when exogenous N-acetylcysteine ​​is provided via GlyNAC-et. Combining GlyNAC-et with an activated B complex simultaneously optimizes the exogenous supply of glutathione precursors (glycine and cysteine ​​via NACET) and the endogenous synthesis of cysteine ​​from methionine, thus maximizing the body's overall capacity to produce glutathione. Furthermore, riboflavin (B2) is a cofactor for glutathione reductase, which regenerates reduced glutathione from oxidized glutathione, completing the catalytic cycle of the glutathione system.

• Seven Zincs + Copper: Zinc and copper play critical but complex roles in glutathione metabolism, requiring a proper balance between the two minerals. Zinc is a structural and catalytic cofactor for enzymes involved in glutathione synthesis, including γ-glutamylcysteine ​​ligase, which catalyzes the rate-limiting step in glutathione biosynthesis. Zinc also participates in regulating the gene expression of antioxidant enzymes and in stabilizing membranes against lipid peroxidation. Copper, for its part, is an essential component of copper-zinc superoxide dismutase (Cu-Zn SOD), a key antioxidant enzyme that converts the superoxide radical into hydrogen peroxide, which is subsequently neutralized by glutathione peroxidases using glutathione as a substrate. This enzyme sequence SOD→GPx illustrates how copper and the glutathione system work together to neutralize reactive species. Critically, the zinc-to-copper ratio must be kept balanced because relative excesses of either can paradoxically compromise glutathione synthesis. The formulation of seven forms of zinc along with copper ensures this balance while providing optimal bioavailability of both minerals to complement the direct precursors provided by GlyNAC-et.

Liver detoxification and conjugation processes

• Molybdenum: Molybdenum is an essential trace element that acts as a cofactor for critical enzymes involved in the metabolism of sulfur-containing amino acids, creating a direct synergy with the glutathione synthesis pathway supported by GlyNAC-et. Sulfite oxidase, a molybdenum-dependent enzyme, catalyzes the oxidation of sulfite to sulfate, the final step in the metabolism of sulfur-containing amino acids such as cysteine ​​and methionine. When molybdenum is inadequate, toxic sulfite can accumulate, interfering with the normal metabolism of sulfur compounds and potentially compromising the availability of cysteine ​​for glutathione synthesis. Furthermore, molybdenum is a cofactor for aldehyde oxidase and xanthine oxidase, enzymes involved in purine metabolism and detoxification processes that generate reactive oxygen species as byproducts, thus increasing the demand for glutathione to neutralize these oxidants. By combining GlyNAC-et with molybdenum, it is ensured that the metabolism of sulfur amino acids proceeds efficiently without the accumulation of toxic intermediates, while maintaining the capacity for glutathione synthesis even under conditions of high metabolic sulfur load derived from the supplement itself.

• Milk thistle extract (silymarin): Silymarin, the flavonolignan complex from milk thistle, exhibits multiple synergistic mechanisms with GlyNAC-et in the context of liver function and glutathione synthesis. Research has documented that silymarin can directly increase hepatic glutathione levels by stimulating the expression of glutathione biosynthetic enzymes and protecting hepatocytes against toxin-induced glutathione depletion. This effect is particularly relevant because the liver has the highest concentrations of glutathione in the body and is the organ where most glycine-glutathione conjugation reactions occur. Silymarin also exerts direct hepatoprotective effects by stabilizing cell membranes, inhibiting lipid peroxidation, and modulating liver regeneration, creating a favorable environment for hepatocytes to optimally synthesize glutathione from precursors provided by GlyNAC-et. Furthermore, by reducing oxidative liver damage, silymarin decreases the consumption of glutathione to repair that damage, allowing newly synthesized glutathione to be used for phase II detoxification and other metabolic functions. This combination is particularly valuable for individuals with high hepatic exposures to xenobiotics, alcohol, or other agents that challenge both the structural integrity and detoxification capacity of the liver.

Bioavailability and absorption

• Piperine: This alkaloid derived from black pepper has been extensively researched for its ability to increase the bioavailability of numerous nutraceuticals by modulating intestinal absorption pathways and hepatic first-pass metabolism. Piperine inhibits cytochrome P450 enzymes and glucuronosyltransferases that metabolize xenobiotics and bioactive compounds, thereby prolonging their half-life and allowing higher concentrations to reach the systemic circulation. Although glycine and N-acetylcysteine ​​generally have good intestinal absorption, piperine could potentially increase their effective bioavailability by reducing their first-pass metabolism, particularly relevant for N-acetylcysteine, which can undergo premature deacetylation. Furthermore, piperine stimulates the secretion of digestive enzymes and increases the intestinal absorptive surface area by affecting villous morphology, which could promote amino acid uptake. For these reasons, piperine is widely used as a cross-enhancing cofactor in herbal supplement and nutraceutical formulations, improving the overall efficacy of the active compounds by ensuring that a greater proportion of the administered dose effectively reaches the target tissues where it will exert its biological effects.

How long should I wait to notice the first effects of GlyNAC-et?

The perceived timing of GlyNAC-et's effects varies considerably depending on the intended use and individual sensitivity. For those seeking overall energy and vitality support, some users report a subtle sense of increased mental clarity and reduced fatigue during the second or third week of consistent use, although these initial effects may be difficult to distinguish from other lifestyle factors. In the context of nighttime sleep support, particularly when taken at night, the influence on sleep quality may begin to be noticeable within the first 5 to 10 days, manifesting as deeper sleep or a more rested feeling upon waking. For goals related to post-exercise muscle recovery, changes in recovery time or a reduction in perceived muscle fatigue may begin to be noticeable after 2 to 4 weeks of regular supplementation combined with consistent training. However, the more profound effects on markers of oxidative stress, mitochondrial function, and collagen synthesis generally require longer periods of 8 to 12 weeks to fully develop and become evident. It is important to maintain realistic expectations and recognize that many of the benefits of GlyNAC-et operate at the cellular level and may not translate into immediately perceptible subjective sensations, even though the processes of cellular protection and repair are occurring from the start of supplementation.

Should I take the capsules together or spaced out throughout the day?

The dosage distribution strategy for GlyNAC-et throughout the day can be optimized according to personal goals and the overall capsule protocol being used. For 2-capsule-daily protocols (1000 mg of glycine + 200 mg of NACET), the most common and generally effective distribution is to take one capsule in the morning with breakfast and another at midday or early afternoon, spacing the doses approximately 6 to 8 hours apart. This strategy maintains a more consistent supply of glutathione precursors throughout the day, supporting the continuous synthesis that occurs in different tissues according to their specific metabolic rhythms. For 3-capsule-daily protocols, the typical distribution would be morning, midday, and afternoon or evening, avoiding concentrating all doses within a short period. However, there are situations where dose concentration can be strategic: some users who prioritize nighttime sleep support choose to take 2 capsules together approximately 60 to 90 minutes before bedtime to maximize the sleep-modulating effects of glycine. For sports recovery, taking 1 or 2 capsules immediately after training takes advantage of the window of heightened protein synthesis. Generally, spaced dosing is preferable for overall antioxidant support and continuous well-being, while concentrated dosing may be appropriate for specific, time-bound applications. Flexibility in timing allows for a customized protocol based on individual lifestyle, while maintaining consistency in daily use.

Can I open the capsules and mix the contents with food or drinks?

While it is technically possible to open GlyNAC-et capsules and mix their contents with food or beverages, this practice presents some important considerations. Both glycine and N-acetylcysteine ​​are amino acids that can have characteristic flavors when directly exposed to the taste buds: glycine has a mildly sweet taste that is generally well-tolerated, but N-acetylcysteine ​​has a distinctive sulfurous taste and odor that many people find unpleasant, particularly when mixed with warm liquids or foods that accentuate these volatile compounds. If you choose this method, it is recommended to mix the contents with strongly flavored cold beverages (such as citrus fruit juices, intensely flavored protein shakes, or flavored plant-based drinks) or incorporate them into dense foods like Greek yogurt, applesauce, or oatmeal, where the flavor can be more effectively masked. It is important to consume the mixture immediately after preparation to prevent the N-acetylcysteine ​​from oxidizing when exposed to air. The capsules are designed to protect the ingredients from the acidic gastric environment during initial transit and allow for more controlled release. Therefore, bypassing this protection could theoretically slightly affect absorption, although the magnitude of this effect is likely minor for these relatively stable amino acids. For individuals with difficulty swallowing capsules, opening and mixing the contents is a valid alternative, but for most users, swallowing the capsules whole with plenty of water is more convenient and palatable.

Is it better to take GlyNAC-et on an empty stomach or with food?

The absorption of glycine and N-acetylcysteine ​​is not significantly impeded by the presence of food, offering considerable flexibility in timing administration. Both amino acids are primarily absorbed in the small intestine via amino acid transporters, and while the presence of a mixed meal may slightly slow the absorption rate (increasing the time to reach peak plasma concentrations), it generally does not reduce the total amount absorbed. For most users, taking GlyNAC-et with main meals offers several practical advantages: it improves adherence by providing reminders of doses along with established eating habits, it can reduce mild digestive discomfort that some people experience with amino acids taken on an empty stomach, and it takes advantage of postprandial metabolic activation when tissues are actively synthesizing proteins and participating in anabolic processes. However, some users report a preference for taking the supplement on an empty stomach (at least 30 minutes before eating or 2 hours after) when seeking potentially faster absorption, particularly in pre-workout contexts or when prioritizing rapid achievement of high circulating precursor levels. Fasting may be especially beneficial for the morning dose, as the stomach is naturally empty after the overnight fast and absorption can proceed without competition from other dietary amino acids via the same transporters. For nighttime doses intended to support sleep, taking the capsules with a light dinner or a small snack 1 to 2 hours before bedtime is an appropriate balance. Ultimately, individual digestive tolerance should guide the decision, with taking it with food being the safest option for those experiencing any gastric sensitivity.

How much water should I drink with each capsule?

It is recommended to take each GlyNAC-et capsule with a full glass of water, at least 200 to 250 ml (approximately 8 ounces), enough to comfortably swallow the capsule and promote its efficient passage through the esophagus into the stomach. The water should preferably be at room temperature or slightly cool, as extremely cold temperatures may cause some esophageal discomfort in sensitive individuals, while very hot water offers no advantages and may be less pleasant for taking supplements. Beyond the mechanical function of facilitating swallowing, drinking enough water with the supplement contributes to the proper dissolution of the capsule shell in the stomach and the adequate dispersion of the released amino acids, promoting their subsequent absorption in the small intestine. Some users find it helpful to drink an additional glass of water 10 to 15 minutes after taking the capsule, especially if taken on an empty stomach, to promote gastric emptying and transit to the site of intestinal absorption. It is important to maintain adequate overall hydration throughout the day (a minimum of 1.5 to 2 liters of water daily, adjusting according to body weight, physical activity, and climate) when using GlyNAC-et, as glutathione synthesis, hepatic conjugation function, and renal elimination of metabolites all depend on optimal hydration. Inadequate hydration can compromise the efficiency of detoxification processes in which glutathione actively participates. Avoid taking the capsule solely with beverages containing caffeine, alcohol, or large amounts of sugar, although a small amount of these beverages along with water is generally acceptable.

Can I combine GlyNAC-et with other antioxidant supplements?

GlyNAC-et can be effectively integrated into supplementation protocols that include other antioxidants, and in fact, many combinations generate beneficial synergies where the different antioxidants work together to provide more comprehensive protection than any single compound. The combination with vitamin C, vitamin E, CoQ10, alpha-lipoic acid, and selenium is particularly well-supported by research documenting synergistic interactions in the "antioxidant network," where these compounds regenerate each other and operate in different cellular compartments (aqueous vs. lipid, cytosolic vs. mitochondrial). When designing a combination protocol, it is advisable to introduce GlyNAC-et first for 5 to 7 days to establish baseline tolerance, and then add other antioxidants one at a time at intervals of several days, allowing for the identification of any interactions or individual effects. It is important to consider the timing of administration of each supplement: some lipophilic antioxidants such as CoQ10 and vitamin E are better absorbed with meals containing fat, while GlyNAC-et can be taken with or without food. Vitamin C can be taken with GlyNAC-et without problems, and in fact, this combination may enhance the regeneration of synthesized glutathione. Minerals such as selenium and zinc, when included, should be taken with food to optimize absorption and tolerance. It is generally unnecessary and potentially excessive to combine GlyNAC-et with oral reduced glutathione supplements, as both aim for the same goal (raising glutathione levels), and the precursors provided by GlyNAC-et are generally more effective at increasing intracellular glutathione than direct oral glutathione, which has limited bioavailability. When combining multiple supplements, pay attention to the body's overall response and adjust dosages or frequencies as needed, remembering that more is not always better and that appropriate synergy is often achieved with moderate doses of multiple complementary compounds rather than maximum doses of each.

Should I take GlyNAC-et continuously or take periodic breaks?

For GlyNAC-et, since it provides precursors to compounds that the body naturally synthesizes and that participate in ongoing physiological functions (glutathione, collagen, neurotransmission), prolonged use without mandatory breaks is generally appropriate and safe, unlike supplements that can lead to tolerance or receptor saturation. However, implementing evaluation periods can be valuable for practical reasons and self-awareness. A common approach involves continuous use for 12 to 16 weeks, followed by an optional 1- to 2-week evaluation where the dosage is reduced to a minimal maintenance dose (1 capsule daily) or discontinued entirely. This allows observation of whether the perceived benefits are partially maintained (suggesting consolidated improvements in baseline antioxidant status) or whether there is a gradual return to previous states (indicating continued dependence on supplemental support). For longevity goals and long-term antioxidant support, many users opt for near-continuous use for years, with brief evaluations every 6 to 12 months rather than regularly scheduled breaks. In contexts of use geared towards sports recovery or periods of high metabolic demand, it may make sense to align use with training macrocycles, implementing unloading periods coinciding with active rest phases. Breaks are not necessary to "reset" receptors or prevent tolerance, as glycine and N-acetylcysteine ​​do not operate through mechanisms that generate cellular desensitization. Rather, the decision to take breaks should be guided by goals such as assessing dependence, economic considerations, or simply the desire to maintain a conscious, rather than automatic, relationship with supplementation. If a break is implemented after prolonged use, there may be a 1- to 3-week period where tissue glutathione levels gradually decline toward pre-supplementation baseline levels, although this decline is typically gradual rather than abrupt and is not associated with discontinuation or rebound symptoms.

What should I do if I forget to take a dose?

If a scheduled dose of GlyNAC-et is missed, the optimal recovery strategy depends on the time elapsed since the usual administration time and how close it is to the next dose. If the missed dose is detected within 2 to 3 hours of the usual time and the meal associated with that dose has not yet been consumed (in protocols where it is taken with food), the capsule can be taken immediately following the normal routine. If more than 3 to 4 hours have passed and the time of the next scheduled dose is approaching (within the next 2 to 3 hours), it is preferable to skip the missed dose entirely and continue with the regular schedule for the next administration. Doubling the dose at the next administration to "compensate" for the missed dose is not recommended, as this creates an irregular dosing pattern that can affect digestive tolerance and provides no significant advantage, given that glutathione synthesis is a continuous process that benefits more from consistent delivery than intermittent peaks. If missed doses are occasional (less than once a week), their impact on overall results is minimal, given that the protocol is based on a model of progressively accumulating benefits rather than effects requiring constant plasma levels. However, if missed doses become frequent (more than two to three times a week), this suggests that the chosen protocol doesn't fit well with your current lifestyle, and it would be worthwhile to consider simplifications such as reducing to a regimen of one or two capsules daily at more memorable times (e.g., only with breakfast and dinner), setting alarms on mobile devices, or creating strong contextual associations (placing the bottle next to the coffee maker, toothbrush, or another place where you pass by daily at specific times). Long-term consistency is more important than perfection in each individual dose.

Can I take GlyNAC-et if I consume coffee or other caffeinated beverages?

There is no evidence of problematic interactions or contraindications between GlyNAC-et and caffeine consumption in its usual forms (coffee, tea, energy drinks, caffeine supplements). Both compounds operate through entirely different mechanisms: caffeine acts primarily as an antagonist of adenosine A1 and A2A receptors in the central nervous system, while glycine and N-acetylcysteine ​​provide metabolic precursors for glutathione synthesis and participate in modulatory neurotransmission and antioxidant processes. Caffeine does not interfere with the intestinal absorption of amino acids or with the enzymes that synthesize glutathione. However, there are some practical considerations for optimizing their combined use. It is preferable to separate the intake of GlyNAC-et from the consumption of large amounts of coffee by at least 15 to 30 minutes to avoid excessive fluid volume in the stomach simultaneously, although this separation is more a matter of comfort than absorption. Consuming strong coffee on an empty stomach could increase gastric acid secretion, which can cause discomfort in some sensitive individuals. This is not directly related to GlyNAC-et but could be mistakenly attributed to the supplement if taken together. Some users seeking sleep support by using GlyNAC-et at night choose to limit their caffeine intake after midday to avoid counteracting the sleep-modulating effects of glycine, although this is more of a general sleep hygiene strategy than a direct interaction. It's important to note that excessive caffeine consumption can, in some individuals, increase oxidative stress and glutathione consumption, theoretically increasing the requirements for glutathione precursors. However, this effect is only relevant at very high consumption levels (more than 400-500 mg of caffeine daily on a sustained basis). In summary, moderate caffeine consumption (up to 300-400 mg daily) is fully compatible with the use of GlyNAC-et, and does not require special adjustments in dosage or timing beyond the considerations of digestive comfort and sleep quality goals mentioned.

Will I experience any side effects during the first few days of use?

Most GlyNAC-et users tolerate the supplement very well from the start, experiencing a smooth transition without noticeable side effects, particularly when following the recommendation to begin with low doses during the 3- to 5-day adaptation phase. However, a small percentage of people may experience mild digestive adjustments during the first week, typically manifested as early satiety, subtle intestinal gas, or minor changes in stool frequency or consistency. These effects, when they occur, are generally transient and resolve spontaneously as the digestive tract adjusts to the increased amino acid supply. Due to its sulfur content, N-acetylcysteine ​​may occasionally produce burps with a mild sulfurous odor in some people during the first few days, an effect that tends to diminish with continued use. Some users report a temporary increase in thirst or a slight change in urine odor during the first week, reflecting changes in the metabolism of sulfur compounds and the excretion of metabolites. This is completely normal and does not indicate any problem. To minimize any digestive adjustment, it is recommended to take the capsules with food during the first week, ensure ample hydration (at least 2 liters of water daily), and if discomfort is experienced, temporarily reduce to a minimum dose (1 capsule daily) before gradually increasing. Significant adverse reactions are extremely rare, but if persistent digestive symptoms occur beyond 10 days, skin rashes develop, or any other reaction causes concern, use should be temporarily discontinued. Glycine, due to its role as an inhibitory neurotransmitter, could theoretically cause mild daytime drowsiness in highly sensitive individuals when taken at high doses during the day, although this is uncommon with standard doses. If this occurs, it can be resolved by redistributing the dose to the evening. Overall, GlyNAC-et has an excellent safety profile with very high tolerability in healthy adult populations.

Can I use GlyNAC-et if I follow a vegetarian, vegan, ketogenic, or intermittent fasting diet?

GlyNAC-et is highly compatible with virtually all dietary patterns, although each dietary approach may have specific considerations for optimizing its integration. For vegetarians and vegans, it is important to verify that the capsule shell is plant-based (cellulose) if strict adherence to these principles is desired, as some capsules use animal-derived gelatin. From a nutritional standpoint, plant-based diets, especially strict vegan diets, may naturally have lower intakes of certain sulfur amino acids if not carefully planned, which could make supplementation with glutathione precursors like GlyNAC-et particularly valuable. For ketogenic diets (very low in carbohydrates, high in fat), GlyNAC-et integrates seamlessly as it provides amino acids with negligible caloric content and no carbohydrates, thus not interfering with ketosis. In fact, some research suggests that oxidative stress may be slightly elevated during the initial phases of adaptation to ketosis, making antioxidant support relevant. Taking the capsules with meals rich in healthy fats typical of ketogenic diets (avocado, olive oil, nuts) presents no problems. For intermittent fasting protocols, the decision to take GlyNAC-et during the fasting window versus the eating window depends on how strict the fast is and the specific goals. Technically, one GlyNAC-et capsule contains minimal calories (approximately 2-3 calories per capsule) that could technically be considered a "break" of a strict fast from a metabolic perspective, although this contribution is so small that many intermittent fasting practitioners consider it negligible. For autophagy- or ketosis-oriented fasts, some purists prefer to take all supplements during the eating window, while others take amino acids during fasting without concern. A practical strategy is to take the first dose with the first meal that breaks the fast and subsequent doses during the eating window. In short, GlyNAC-et is remarkably flexible and can be adapted to virtually any eating pattern with minor adjustments to the timing of administration.

What is the best time of day to take GlyNAC-et if I am looking for nighttime sleep support?

To specifically optimize glycine's effects on sleep quality and circadian rhythm regulation, the timing of administration requires a different strategy than the standard daytime distribution protocol. Research on glycine and sleep suggests that administration in the pre-night period, approximately 60 to 120 minutes before the usual bedtime, may promote the transition to deep sleep by activating glycine receptors in the suprachiasmatic nucleus of the hypothalamus and promoting peripheral vasodilation, which facilitates the dissipation of body heat. A targeted sleep protocol would consist of taking 1 to 2 capsules (500–1000 mg of glycine + 100–200 mg of NACET) within this pre-night window, ideally at the same time each night to support circadian regularity. Some users find that taking the capsules with an early light dinner (for example, at 7-8 PM if planning to go to sleep at 10-11 PM) works well, while others prefer to take them as part of a sleep-preparation routine closer to bedtime, accompanied only by warm water or a relaxing herbal infusion. It is important to avoid combining the nighttime dose with very large or heavy meals that require prolonged digestion, as this could delay absorption and reduce its effectiveness for sleep. If using a multi-capsule daily protocol for goals other than sleep, a common distribution would be 1 capsule in the morning for daytime metabolic support and 1-2 capsules in the evening for sleep modulation. During the first few days of this nighttime protocol, some people experience mild sleepiness earlier than their usual pattern, which can be taken advantage of by gradually adjusting bedtime to an earlier time if desired. It is important to maintain other sleep hygiene practices simultaneously (cool and dark environment, blue light reduction, consistent schedules) since GlyNAC-et works best as part of a comprehensive sleep optimization approach rather than as an isolated solution.

Do I need to adjust the dose if I weigh significantly more or less than average?

Unlike certain pharmaceutical compounds where dosage is strictly calculated based on body weight, supplementation protocols with amino acid precursors like GlyNAC-et typically use standardized dosage ranges that have demonstrated effectiveness in individuals of varying body weights. Research dosages exploring the combination of glycine and N-acetylcysteine ​​are frequently expressed in terms of body weight (e.g., approximately 1.33 mmol/kg/day of glycine and 0.81 mmol/kg/day of NAC in studies with older adults), which would equate to total doses that vary from person to person. However, in supplementation practice, standardized absolute doses (such as those provided by 2 to 3 capsules daily) are generally used, which fall within safe and effective ranges for most adults. That said, there are some reasonable practical considerations. Individuals with a significantly lower body weight than average (less than 50-55 kg) can start with doses at the lower end of the recommended range (1 to 2 capsules daily) and increase only if tolerance is excellent and their goals justify it. On the other hand, individuals with a substantially higher body weight (over 90-100 kg) or with high muscle mass (such as strength athletes) may benefit from doses at the higher end of the range (3 capsules daily) or even consider 4-capsule protocols in contexts of very high metabolic demand, always implementing gradual increases. It is important to recognize that factors beyond simple body weight influence glutathione requirements, including exposure to oxidative stress (intense exercise, environmental pollution, psychological stress), the efficiency of individual metabolic pathways, and the presence of increased demands for collagen synthesis or detoxification processes. Therefore, the optimal dose should be determined more by the individual's perceived response and specific goals than by a rigid formula based solely on weight. Starting with moderate doses and gradually adjusting based on tolerance and perceived effects represents a more personalized and generally more effective approach than theoretical calculations based solely on body weight.

Can I take GlyNAC-et if I work night shifts or have irregular hours?

GlyNAC-et can be effectively adapted to non-traditional work patterns, although it requires strategic planning of administration timing that synchronizes with the individual's activity-rest cycle rather than a conventional clock. The fundamental principle is to align doses with metabolically relevant times of the day: the wake-up/activation period, the mid-day activity period, and the period of preparation for rest, regardless of whether these occur during daylight or nighttime hours. For permanent night shift workers (those who always work nights and sleep during the day), the protocol should reflect their reversed chronobiology: their metabolic "morning" is when they wake up in the late afternoon/evening, and they can take the first dose upon waking, a second halfway through their night shift, and potentially a third before going to sleep in the morning if they are seeking sleep support. For individuals with rotating shifts that alternate weekly between days and nights, the strategy is more challenging but still manageable: during night shifts, adjust dosing to the nighttime cycle as described above, and during day shifts, revert to the conventional protocol. During transitions between shifts (adjustment days), maintain at least one daily dose at a consistent time as an anchor, and be flexible with the others. For completely irregular schedules with no predictable pattern, a robust strategy involves establishing two simple rules: always take 1 capsule within the first hour after waking (whenever that may be), and 1 capsule approximately 6 to 8 hours later, with an optional third capsule before bed if using the 3-capsule protocol. Consistency in the pattern relative to one's sleep-wake cycle is more important than consistency at specific clock times. It is important to recognize that irregular or night shift workers face increased circadian and metabolic challenges, including potentially greater oxidative stress, which could make the antioxidant support provided by GlyNAC-et particularly valuable in these populations. Maintaining adequate hydration, appropriate light exposure according to the activity cycle, and regular nutrition are also critical factors for optimizing well-being in challenging chronobiological contexts.

What should I observe or monitor to know if GlyNAC-et is working?

Establishing clear and observable markers facilitates an objective assessment of whether GlyNAC-et is supporting personal wellness goals, although it's important to recognize that many of its effects operate at the cellular level and may not translate into dramatically noticeable changes in the short term. For goals related to energy and general vitality, useful markers include perceived energy levels throughout the day (particularly during the evening when many people experience dips), the ability to maintain focus on cognitively demanding tasks, and the feeling of being refreshed upon waking in the morning. Keeping a simple daily energy log on a scale of 1 to 10 for the first few weeks can reveal subtle trends that might otherwise go unnoticed. For goals related to sleep quality, observe sleep latency (time to fall asleep), number and duration of nighttime awakenings, perceived sleep depth, and quality of waking (rested vs. groggy). Some people find it helpful to use sleep-tracking devices for more objective data on sleep architecture, although subjective perceptions are equally valuable. For sports recovery and physical performance goals, monitor perceived recovery time between training sessions, the severity and duration of delayed onset muscle soreness (DOMS), the ability to maintain training volume or intensity week after week, and possibly objective performance markers such as weights lifted or times in specific circuits. For skin and connective tissue-related goals, observe changes in perceived skin elasticity, the appearance of fine lines, the speed of healing from minor cuts or scrapes, and, in athletes, the frequency of joint or tendon discomfort. It is important to establish these observations for the first 1 to 2 weeks as a baseline and then review progress every 3 to 4 weeks, maintaining realistic expectations about the rate of change. Dated photographs (for aesthetic skin goals), detailed training logs (for sports goals), or simple wellness journals can provide concrete data for assessing progress. Recognizing that the absence of deterioration in contexts of high oxidative stress (aging, intense training, environmental exposures) can itself be an indicator of effectiveness, although less dramatic than active improvements.

Does GlyNAC-et interfere with alcohol consumption, or should I avoid combining them?

GlyNAC-et has no absolute contraindications with occasional and moderate alcohol consumption, although there are important metabolic interactions that warrant careful consideration. The liver metabolizes alcohol through enzymatic systems that generate acetaldehyde (a toxic metabolite) and subsequently convert it to acetate, processes that consume large amounts of glutathione and generate significant oxidative stress. The glutathione system is critical for neutralizing acetaldehyde and protecting hepatocytes from alcohol-induced damage. In this context, maintaining adequate glutathione levels by supplying precursors such as those provided by GlyNAC-et could theoretically support the liver's detoxification capacity during episodes of alcohol consumption. However, it is crucial not to interpret this as "protection" that permits excessive alcohol consumption, as no supplement can completely mitigate the deleterious effects of heavy or chronic alcohol use. For moderate occasional consumption (1 to 2 standard drinks on one occasion, less than 2 to 3 times per week), continuing GlyNAC-et according to the usual protocol is generally appropriate. Some users choose to take an additional dose of GlyNAC-et before an event where they plan to consume alcohol, although evidence of a specific benefit from this timing is limited. It is important to avoid taking GlyNAC-et simultaneously with large amounts of alcohol (e.g., during a heavy drinking session), as this could cause digestive upset due to the combination. A reasonable strategy would be to take the regular dose of GlyNAC-et in the morning or at midday, and if alcohol consumption is planned for the evening, allow several hours between doses. For individuals who consume alcohol frequently or in amounts that exceed public health recommendations, it is important to recognize that supplemental support is not a substitute for addressing the underlying drinking pattern. Chronic alcohol use depletes hepatic glutathione in a sustained manner and can interfere with multiple aspects of amino acid metabolism, potentially reducing the effectiveness of GlyNAC-et despite supplementation.

Can I use GlyNAC-et during pregnancy or breastfeeding?

Specific information on the safety of GlyNAC-et during pregnancy and lactation is limited, as controlled clinical studies generally exclude pregnant and breastfeeding women for ethical reasons. Both glycine and N-acetylcysteine ​​are compounds involved in normal bodily metabolism, and both amino acids occur naturally in dietary proteins. However, concentrated doses in supplements significantly exceed the amounts that would be obtained from food alone, and the effects of these high doses during critical periods of fetal development or on the composition of breast milk have not been thoroughly characterized. N-acetylcysteine ​​has been used medically in specific contexts during pregnancy (e.g., for acetaminophen poisoning) under strict medical supervision, suggesting that it is not inherently teratogenic, but its routine supplemental use in healthy pregnant women is not well studied. During pregnancy, metabolic demands and glutathione synthesis increase to support both the mother and the developing fetus, and theoretically, supporting these systems with precursors could be beneficial, but this hypothesis has not been validated in formal research. Conservative caution suggests avoiding the introduction of new supplements during pregnancy, especially during the first trimester when organogenesis is most sensitive to external influences. For women who were already using GlyNAC-et before a confirmed pregnancy, it is prudent to discontinue use until the situation can be discussed with the prenatal care team. During lactation, although it is theoretically unlikely that supplemental amino acids will have adverse effects on the infant through breast milk, again, the lack of specific data advises caution. Priorities during pregnancy and lactation should focus on balanced whole-food nutrition, standard prenatal supplementation (folic acid, iron, vitamins), and lifestyle modifications supported by strong evidence. Any consideration of supplementation beyond the standard prenatal protocol requires individual risk-benefit assessment by professionals with specific case knowledge.

How long should I maintain the rest period between cycles if I decide to do them?

If structured cycles of GlyNAC-et use with interspersed rest periods are chosen, the appropriate rest period duration must balance several objectives: allowing for an assessment of baseline status without supplementation, observing how long the accumulated benefits are maintained, and providing a window for the body to demonstrate its autonomous ability to maintain glutathione levels without exogenous support. For 8- to 12-week cycles (the typical initial duration), a 1- to 2-week rest period is generally sufficient for these evaluative purposes. During this brief rest, tissue glutathione levels will begin to gradually decline toward pre-supplementation baseline levels, a process that typically takes several days to 1 to 2 weeks depending on the specific tissue, with some rapidly turning over tissues (such as erythrocytes) showing faster changes than slowly turning over tissues. Observing whether there are noticeable changes in energy, muscle recovery, sleep quality, or any other marker that was being monitored during this break provides valuable information about the degree of dependence on the supplement versus the consolidation of improvements in baseline antioxidant status. For longer cycles (16 to 24 weeks), a slightly longer break of 2 to 3 weeks may be warranted to allow for a more complete "reset." Some people opt for more spaced-out and longer breaks, using GlyNAC-et for 3 to 6 continuous months followed by a 1-month break, particularly if they are combining multiple supplements and wish to assess the specific contribution of each. It is important to recognize that breaks are not mandatory from a safety or tolerance prevention perspective, but rather represent a tool for self-awareness and ongoing evaluation. During the break, if a significant return of symptoms or conditions that had improved with supplementation is observed, this indicates that continued support is valuable and may justify longer periods of use with less frequent breaks. When resuming after a break, you can restart directly with the maintenance dose without needing to repeat the initial adaptation phase if the previous tolerance was optimal, although starting with a reduced dose for 2 to 3 days is a reasonable option for cautious individuals.

Is it normal to notice changes in body odor, breath, or urine during use?

Some people may notice subtle changes in the odor of their urine, breath, or even slight alterations in body odor during the first few weeks of using GlyNAC-et. These phenomena are related to the metabolism of sulfur compounds present in N-acetylcysteine ​​and do not indicate any health problem. N-acetylcysteine ​​contains sulfur in its molecular structure, and when metabolized, it generates various sulfur compounds that are eventually excreted, some of which have perceptible characteristic odors. Sulfur metabolism can produce volatile compounds such as sulfides and methyl mercaptan, which are partially excreted by the lungs (contributing to changes in breath) and by the kidneys (altering the odor of urine). These changes are typically most noticeable during the first or second week of use and tend to lessen over time as the body adapts to the increased flow of sulfur compounds. The intensity of these changes varies considerably among individuals and can be influenced by factors such as hydration status (more concentrated urine due to insufficient hydration intensifies odors), the composition of the gut microbiota (which participates in sulfur metabolism), and the dosage used. To minimize these effects, ensuring ample hydration (at least 2 to 2.5 liters of water daily) dilutes urinary metabolites and reduces their odor concentration. Taking the capsules with food appears to reduce the intensity of breath changes in some people. Consuming foods rich in chlorophyll (green vegetables) or aromatic herbs (parsley, mint) may help neutralize odors associated with sulfur metabolism. It is important to distinguish between these normal, benign metabolic changes and odor changes associated with medical problems: changes related to GlyNAC-et are generally subtle, non-progressive (they do not worsen week after week), and are not accompanied by other symptoms such as pain, urinary discomfort, or general malaise. If olfactory changes are pronounced, persist beyond 2 to 3 weeks, or cause significant social discomfort, consider reducing the dose to a minimum (1 capsule daily) and assessing whether this mitigates the effect while maintaining perceived benefits, or alternatively, discontinue use. For most users, these effects are minimal or imperceptible and do not pose a barrier to continued use.

Should I take GlyNAC-et before or after exercise to optimize recovery?

The optimal timing of GlyNAC-et in relation to exercise depends on the specific goals being pursued and how it is integrated into the overall daily protocol. To maximize support for muscle recovery and post-exercise protein synthesis, there is a theoretical basis for taking a dose immediately after training (within 30 to 60 minutes), taking advantage of the "anabolic window" where muscles have heightened nutrient sensitivity and increased protein synthesis rates. During this period, providing glycine (an important structural component of collagen and involved in protein metabolism) along with glutathione precursors could support both the repair of muscle structures and the neutralization of oxidative stress generated by intense exercise. Many athletes combine GlyNAC-et with their post-workout protein shake to take advantage of this synergy. However, there is also an argument for pre-workout administration: taking a dose 30 to 60 minutes before exercise ensures that precursors are available in circulation during the period of peak reactive oxygen species generation during exercise itself, potentially limiting oxidative damage in real time rather than just repairing it afterward. An integrated strategy combining both approaches could consist of 1 capsule 45 minutes pre-workout and 1 capsule immediately post-workout on training days, with 1 to 2 capsules typically spaced out on rest days for ongoing support of recovery and adaptation. It is important to recognize that the overall nutritional context is more important than the precise timing of an individual supplement: ensuring adequate total protein intake (approximately 1.6 to 2.2 g/kg of body weight for athletes), sufficient carbohydrates to replenish glycogen, proper hydration, and adequate rest are primary factors in recovery, with GlyNAC-et functioning as a valuable complement rather than the determining factor. For individuals who train very early in the morning on an empty stomach, taking GlyNAC-et immediately after training with their first meal of the day is a practical and effective protocol. Individual experimentation over several weeks with different timings, while monitoring subjective recovery markers (muscle soreness, fatigue, ability to train intensely in consecutive sessions), can reveal which approach works best for each person within their specific training and recovery context.

Can GlyNAC-et cause dependence or discontinuation syndrome if I stop taking it?

GlyNAC-et does not produce physical or psychological dependence in the pharmacological sense of the term, as it provides precursors of compounds that the body synthesizes naturally through physiological metabolic pathways, rather than acting on receptors that can become desensitized or generate compensatory adaptations. Both glycine and N-acetylcysteine ​​participate in normal metabolic processes without creating altered states of consciousness, euphoria, or changes in the brain's reward systems that characterize substances with addictive potential. Upon discontinuing GlyNAC-et use after prolonged periods, there is no "withdrawal syndrome" with unpleasant physical symptoms that compel continued use. What may occur is a gradual return to baseline glutathione and glycine levels that existed before supplementation began, a process that typically takes from several days to two to three weeks, depending on the specific tissue. This return to baseline may manifest as a gradual loss of the benefits experienced during use (for example, improved muscle recovery or increased mental clarity may gradually return to previous levels), but this simply represents the cessation of supplemental support rather than a "rebound" effect or a decline below the original state. Some people describe feeling "less optimal" upon discontinuation, but this reflects having become accustomed to a state of enhanced well-being supported by the supplement rather than a true physiological dependence. It is analogous to ceasing regular exercise: the benefits of exercise are gradually lost without experiencing withdrawal symptoms; one simply returns to a sedentary baseline. To minimize any noticeable transition upon discontinuation after prolonged use, a gradual reduction can be implemented (for example, going from 3 capsules to 2, then to 1, then to none, with 1 to 2 weeks at each step), although this is not strictly necessary and abrupt discontinuation is perfectly safe. The ease of discontinuing without adverse consequences is actually a positive feature that distinguishes nutritional supplements like GlyNAC-et from compounds with more potent and specific pharmacological effects.

RECOMMENDATIONS

• Store the product in a cool, dry place, protected from direct sunlight, moisture and heat sources, keeping the ambient temperature below 25°C to preserve the stability of the amino acids and prevent oxidative degradation of N-acetylcysteine.
• Keep the container tightly closed after each use, ensuring that the lid is properly tightened to minimize exposure to atmospheric oxygen that could affect the quality of the sulfur components of the product.
• Keep out of reach of children and pets, storing the bottle in a high place or in a childproof locking cabinet to prevent unsupervised access.
• Check the expiry date printed on the packaging before starting use and do not consume the product after this date, as the potency and stability of the amino acid precursors cannot be guaranteed beyond the stated validity period.
• Always start with the minimum recommended dose during an adaptation phase of 3 to 5 days (1 capsule daily) to assess individual digestive tolerance before gradually increasing to maintenance or advanced doses according to personal goals.
• Take each capsule with a full glass of water (200-250 ml) to facilitate proper swallowing and promote adequate dissolution in the digestive tract, thus improving the bioavailability of the amino acids.
• Maintain adequate hydration while using this supplement, consuming at least 1.5 to 2 liters of water daily, as the processes of glutathione synthesis, liver detoxification, and renal elimination of metabolites depend on an optimal hydration state.
• Distribute doses throughout the day when using multi-capsule protocols, spacing doses approximately 6 to 8 hours apart to maintain a more constant supply of precursors and optimize continuous glutathione synthesis in different tissues.
• Integrate supplementation within a balanced dietary pattern rich in quality protein, antioxidant vegetables, healthy fats and complex carbohydrates, recognizing that GlyNAC-et complements but does not replace comprehensive nutrition.
• Consider implementing evaluation periods every 12 to 16 weeks of continuous use, with optional 1- to 2-week breaks to observe if the benefits are partially maintained and to evaluate the individual relationship with supplementation.
• Documenting personal response during the first few weeks through simple records of energy, sleep quality, physical recovery, or other relevant markers according to the objectives, thus facilitating objective evaluation of effectiveness and personalization of the protocol.
• Inform health professionals about the use of this supplement if multiple products are being taken concurrently or if there are particular health conditions that require regular monitoring of metabolic parameters.

WARNINGS

• Do not exceed the total dose of 4 capsules daily (2000 mg of glycine + 400 mg of NACET) without having previously assessed tolerance with lower doses and without there being specific objectives that justify high doses.
• Discontinue use immediately if unusual adverse reactions occur, persistent digestive discomfort beyond 10 days of adaptation, skin rashes, or any symptoms that cause significant concern.
• Do not use this product as a substitute for a varied and balanced diet, nor as the sole strategy for addressing wellness goals that require comprehensive approaches including nutrition, exercise, rest and stress management.
• Avoid use during pregnancy due to the absence of specific clinical studies evaluating the safety of supplemental doses of glycine and N-acetylcysteine ​​in pregnant women and their effects on fetal development.
• Do not use during breastfeeding due to a lack of information on the transfer of these amino acids in supplemental concentrations to breast milk and their possible effects on infants.
• Do not use if there is a known hypersensitivity or previous allergic reactions to N-acetylcysteine, glycine, or any component of the capsule formulation.
• Avoid concomitant use with therapeutic doses of nitroglycerin or other nitric oxide donors, as N-acetylcysteine ​​could theoretically potentiate the vasodilatory effects of these compounds.
• Do not chew, bite, or hold the capsules in your mouth before swallowing; always swallow them whole with water to avoid prolonged exposure of the concentrated N-acetylcysteine ​​extract to the oral mucosa, which has an unpleasant taste and smell.
• Discontinue use at least 2 weeks before any scheduled surgical procedure to allow glutathione levels and clotting functions to return to their baseline state without influence from supplementation.
• Avoid combining with excessive or chronic alcohol consumption (more than 2 to 3 standard drinks daily on a regular basis), as alcohol depletes liver glutathione in a sustained manner and can interfere with the proper metabolism of sulfur amino acids.
• Do not combine with multiple new supplements simultaneously; introduce GlyNAC-et first for at least one week before adding other products in order to clearly identify individual responses to each component.
• People with a history of cystine kidney stones should use this product with caution, as N-acetylcysteine ​​provides cysteine ​​which in susceptible individuals could theoretically contribute to the formation of this specific type of stone.
• Do not use as a strategy to "compensate" or "protect" against deliberate consumption of toxic substances, including excessive alcohol, tobacco, or recreational drugs, as no supplement can completely mitigate the harm caused by these exposures.
• Maintain realistic expectations about the pace and magnitude of perceived effects, recognizing that the benefits of GlyNAC-et operate primarily at the cellular level and may require several weeks or months of consistent use to become evident.
• If the packaging shows signs of tampering, the capsules show significant changes in color or appearance, or the product develops an abnormal odor different from the mild sulfurous odor characteristic of N-acetylcysteine, do not consume and contact the supplier.
• The effects perceived may vary between individuals; this product complements the diet within a balanced lifestyle.

• The use of GlyNAC-et during pregnancy is discouraged due to the absence of controlled clinical studies specifically evaluating the safety of supplemental doses of glycine and N-acetylcysteine ​​in pregnant women, as well as the lack of information on possible effects on fetal development or metabolic adaptations typical of pregnancy.
• Use during breastfeeding is discouraged due to insufficient evidence on the transfer of these amino acids in supplemental concentrations to breast milk and the lack of data on possible effects on infants exposed through breastfeeding.
• Avoid use in people with known hypersensitivity to N-acetylcysteine, glycine, or any component of the capsule formulation, including capsule shell materials, given the risk of hypersensitivity reactions that may manifest as skin rashes, itching, or in rare cases, more significant reactions.
• Do not combine with therapeutic doses of nitroglycerin or other organic nitric oxide donors (such as nitroprusside, isosorbide dinitrate, isosorbide mononitrate), as N-acetylcysteine ​​could potentiate the vasodilatory effects of these compounds through mechanisms involving the formation of S-nitrosothiols and modulation of nitric oxide bioavailability.
• Avoid concomitant use with activated charcoal administered for acute detoxification purposes, as activated charcoal can adsorb N-acetylcysteine ​​in the gastrointestinal tract, significantly reducing its absorption and bioavailability, thus compromising the effectiveness of the supplement.
• Use is discouraged in people with a history of cystine kidney stones (cystinuria), a rare genetic condition characterized by excessive urinary excretion of cystine that can crystallize and form stones, since N-acetylcysteine ​​provides cysteine ​​which in individuals with this specific amino acid transport disorder could theoretically contribute to urinary cystine load.
• Avoid use in people with severe uncontrolled asthma who have a documented history of inhaled N-acetylcysteine-induced bronchospasm, although this sensitivity is more relevant for nebulized forms than for oral supplements, it could indicate an individual susceptibility to sulfur compounds that warrants caution with oral forms.
• Do not use before scheduled surgical procedures (discontinue at least 2 weeks prior), considering that N-acetylcysteine ​​and elevated glutathione could theoretically interfere with aspects of perioperative management of oxidative stress and the controlled inflammatory response that is part of the surgical healing process.
• Use is discouraged in people requiring strict monitoring of coagulation parameters under intensive anticoagulant therapy, although there is no direct evidence of significant interaction, prudence advises avoiding introducing additional variables in situations where coagulation stability is critical.
• Avoid concomitant use with aminoglycoside antibiotics (gentamicin, tobramycin, amikacin) in contexts of prolonged therapeutic use, as it has been documented that N-acetylcysteine ​​can potentially form complexes with these antibiotics, although the clinical relevance of this interaction with supplemental oral doses is uncertain.
• No other specific, well-established contraindications have been identified based on the available evidence for oral supplemental doses of glycine and N-acetylcysteine ​​in healthy adults; use responsibly according to the directions for use and recommendations provided.